San Diego, Ca., USA - October 10, 2015, San Diego, Ca., USA - Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced that Peter Greenleaf has been appointed to the company's board of directors.
Article continues below
Mr. Greenleaf brings to Mast Therapeutics' Board of Directors over 20 years of experience in the biopharmaceutical industry, including a track record of effective leadership through periods of significant growth and extensive global commercial operations, strategic planning, and product development expertise.
Mr. Greenleaf currently serves as Chief Executive Officer and member of the Board of Directors of Sucampo Pharmaceuticals, Inc. which is focused on the development and commercialization of medicines to meet major unmet medical needs of patients worldwide.
Prior to joining Sucampo, Mr. Greenleaf served as Chief Executive Officer and member of the Board of Directors of Histogenics Corporation, a regenerative medicine company.
Prior to Histogenics, Mr. Greenleaf was employed by MedImmune LLC, the global biologics arm of AstraZeneca from 2006 to 2013, where he most recently served as President and where he was instrumental in the sale of MedImmune to AstraZeneca in 2007.
While at MedImmune, Mr. Greenleaf drove the expansion of MedImmune's pipeline into over 120 clinical and pre-clinical programs and the commercialization of its marketed products. He also served as President of MedImmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group.
Prior to serving as President of MedImmune, Mr. Greenleaf was the Chief Commercial Officer of the company, responsible for its commercial, corporate development and strategy functions. He has also held senior commercial roles at Centocor Biotech, Inc. (now Jansen Biotechnology, Johnson & Johnson) and Boehringer Mannheim G.m.b.H. (now Roche Holdings).
Mr. Greenleaf currently chairs the Maryland Venture Fund Authority, whose vision is to oversee implementation of InvestMaryland, a public-private partnership to spur venture capital investment in the state.
Mr. Greenleaf is also a member of the Board of Directors of the Biotechnology Industry Organization (BIO), where he serves on the Governing Boards of the Emerging Companies and Health Sections. ■